Cannabis is one of many plants that produce chemical compounds we know as cannabinoids and terpenes. Not surprisingly, compounds from other plants in the Cannabaceae plant family can affect the body’s endocannabinoid system (ECS) much like those found in cannabis. The ImmunAG™ Tablet is the first pharmaceutical grade Cannabidiol (CBD) product available on the market that was derived from a non-cannabis plant source. The company unveiled this groundbreaking new product at the MJBiz conference in Las Vegas, Nevada last week.
Isodiol, the bioactive pharmaceutical company that is responsible for developing ImmunAG™ – a pharmaceutical grade CBD derived from hops and blended with FDA-approved food additives β-Caryophyllene and α-Humulene. The extract was achieved after years of trial and error and has officially been verified for its bioactivity, or how it affects the human body. This bioactivity was maintained using a specific, proprietary method of extraction and purification that is being kept under wraps for now. Isidiol claims that they can now separate CBD in such a way that it maintains a more effective and pure molecular structure than CBD extracted from cannabis.
Improper processing or extracting from an inactive source can drastically affect the eventual outcome on the CB2 receptors. So now that they can successfully extract CBD from the hops plant, the company is breeding hops plants that naturally develop higher concentrations of CBD. ImmunAG™ is available for purchase online for anyone looking to explore the world of cannabinoid wellness without even touching the cannabis plant. It promises to help the body maintain homeostasis which should help our system regulate against illness. The tablets also serve as a nonspecific phyto-immunotherapy agent.
The team at Isodiol is quite confident that this is just the beginning of non-cannabis derived CBD supplements because of the very obvious draw: hops aren’t illegal in any country. This type of breakthrough is amazing as it helps us not only understand the ECS more deeply, but it also points to the incredible future that is ahead for plant medicine.
Cara began working in the retail cannabis industry of San Francisco, CA in 2011 and continued in that sector for years. In 2015 she put down her budtender hat and dedicated herself to writing full-time. Her passion for the written word and deep respect for the healing properties of the cannabis plant fuel the passion in her posts.